Gut Talk

Sameer K. Berry, MD, and William D. Chey, MD, host this Healio podcast that provides busy clinicians with quick updates that directly affect their GI practices. Through interviews and candid conversations, they explore how health policy, social media, technology, nutrition, practice management and research impact the field of Gastroenterology. Most importantly, the show also features interviews with patients to add a unique perspective on the topics that matter.

Embracing serendipity and a change mindset with William Chey, MD 02/20/2026

Embracing serendipity and a change mindset with William Chey, MD In this special podcast episode, Gut Talk host Sameer Berry, MD, interviews his co-host William Chey, MD, to look back at the lessons learned throughout the milestones in his career, and discuss what lies ahead for his year as ACG president. · Intro 1:11 · Looking back, are there Gut Talk episodes that stand out to you as being particularly memorable? 1:55 · Berry and Chey on common themes in past episodes. 4:46 · Where did you grow up and what were your childhood/early adult years like? 9:19 · Do you think your father being a division chief inspired you? 14:01 · Were there other times your father influenced you? 15:10 · Tell us more about the decisions you have made throughout your training […] Were there other influences that still guide you today? 16:58 · Are there lessons that your mentors left you with in terms of how to be a leader and think creatively? 19:50 · What about guidance you have given as a mentor? […] What advice would you give to those who want to have a leadership career within academics in today’s climate? 22:10 · What does the honor of being ACG president mean to you? How did your involvement with the ACG come to be? 26:58 · What does the day-to-day look like as president of the college, and what are some of the key initiatives you are going to work on this year? 30:29 · What are some of the things that excite you most for the future of the college, the GI specialty and the health care industry? 34:26 · Thank you, Bill 37:33 · Thanks for listening 37:55 William D. Chey, MD, AGAF, FACG, is chief and professor in the division of gastroenterology and hepatology at the University of Michigan, where he leads research on diet and nutrition and their impact on functional bowel disorders. He is also co-host of Healio's Gut Talk podcast. Chey is the president of the for the 2025–2026 term. We’d love to hear from you! Send your comments/questions to . Follow us on X . Disclosures: Berry and Chey report no financial disclosures. /episode/index/show/guttalk/id/40163190

Lessons in Gratitude with Steven Leach, MD 12/17/2025

Innovations in GI Cancer Screening with Paul Limburg, MD 11/19/2025

Innovations in GI Cancer Screening with Paul Limburg, MD In this podcast episode, Paul Limburg, MD, MPH, discusses the movement from academics to industry, developments in colorectal cancer screening tools and more. • Intro 1:11 • Paul Limburg, MD, MPH 1:17 • How did your early influences and childhood years lead you to become interested in gastroenterology and the career you have today? 1:34 • Who were your early inspirations? 2:14 • How did you transition from a career in academics and sciences to a life on the commercial side? 3:34 • How did your role at Exact Sciences come about? 5:58 • Was it a hard decision to take a new position? 7:47 • Chey and Limburg on the joy of advancing science and innovation. 9:03 • Were there any cultural differences that shocked you about the ways work is done in your previous and current positions? 10:10 • Do you see Exact outsourcing scientific research as the company grows? 12:12 • What does a typical day look like for you at Exact? […] What are you responsible of as the leading physician? 13:28 • From a product standpoint, what is ahead on the roadmap for Exact Sciences? […] What are you most excited about regarding next-generation multi-target stool testing and its impact? 15:14 • How do you respond to gastroenterologists’ skepticism and concerns surrounding stool-based screening? 21:15 • What about addressing the concerns surrounding how we can ensure patients with a positive FIT test go in for a colonoscopy? 23:22 • How much of an issue are language barriers when it comes to screening tools? 28:11 • Can you talk about how Exact Sciences are using AI and the evolution of the microbiome internally or in product development? 29:42 • Do you see a future for stool-based testing in between/in combination with colonoscopies? 32:59 • Have you noticed differences in sensitivity and specificity based on age? 34:07 • What are your thoughts on making these tools available in a direct-to-consumer offering? […] How do you make these screening tools more readily available while weighing the usage risks? 35:08 • What is the rate of patients who have a positive stool-based test getting a colonoscopy? 38:44 • If you were talking to a GI fellow deciding to make the jump to industry, what do you tell them? 41:58 • Thank you, Paul 44:55 • Thanks for listening 45:21 Paul J. Limburg, MD, MPH, is chief medical officer for screening at Exact Sciences and emeritus professor of Medicine at Mayo Clinic. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Dr. Limburg, follow and on X. Disclosures: Chey and Berry report no relevant financial disclosures. Limburg reports he is an employee of Exact Sciences. /episode/index/show/guttalk/id/39093215

Reflections on GI workforce, leadership and goalsetting with ACG President Amy Oxentenko, MD 10/22/2025

Reflections on GI workforce, leadership and goalsetting with ACG President Amy Oxentenko, MD In this podcast episode, Amy Oxentenko, MD, discusses her initiatives as ACG president, addressing workforce challenges in the GI space and more. • Intro :50 • Amy Oxentenko, MD 1:09 • How does it feel to be finishing your year as ACG president? 1:54 • What were your main initiatives and goals for this year, and how did they go? 3:28 • Is there a teaser you can give us for what you will reveal at the ACG annual meeting? 8:39 • Chey and Oxentenko on the critical role of additional research within the future of gastroenterology. 12:01 • What research has the college conducted to better understand the true clinical FTE available to patients? […] Are there certain solutions that have stood out to you in your work? 13:19 • Will there be a task force to comment on the rise of clinicians choosing to participate in more of a locum tenens practice? 18:35 • Can you speak about the recent progress made toward addressing the gender gap in GI? 21:32 • What can listeners do in this political climate to continue to make strides towards equity in the field? 25:47 • What have you learned about yourself in the past year as ACG president? 30:09 • What are you optimistic about in GI after this year? 33:19 • On the other hand, what are you most concerned about for gastroenterology? 36:17 • Any advice for the next ACG president? 39:31 • What is next for you? 41:18 • Thank you, Amy 43:10 • Thanks for listening 43:52 Amy Oxentenko, MD, FACP, FACG, AGAF, is a professor of medicine and vice dean of Mayo Clinic Practice. She is a member of the ACG board of trustees and executive team, serving as ACG president from October 2024-October 2025. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Dr. Oxentenko, follow on X. Disclosures: Chey, Berry and Oxentenko report no relevant financial disclosures. /episode/index/show/guttalk/id/38740050

Irritable Bowel Syndrome and Beyond: Food The Main Course 2025 Live Recap (Crossover with Tuesday Night IBS) 08/27/2025

Irritable Bowel Syndrome and Beyond: Food The Main Course 2025 Live Recap (Crossover with Tuesday Night IBS) In this special crossover podcast episode, Tuesday Night IBS hosts Jeffrey Roberts, MSEd, BSc, Erica Dermer and Kate Scarlata, MPH, RDN, are joined live by William Chey, MD, and Amanda Lynett, MS, RDN, at FOOD the Main Course Conference in Ann Arbor, MI. • Intro :02 • About Scarlata :30 • About Chey 1:07 • About Lynett 1:49 • Chey, what are your goals for this year’s FOOD the Main Course Conference? 2:58 • How do you feel that mechanisms of diet are affecting microbiomes? 5:37 • Amanda, what have you learned over the years as you have put together this conference, and how do you think this experience has shaped a more well-rounded program for clinicians? 8:23 • What are you personally going to take away from the conference this year? 11:17 • A discussion on peer-to-peer interactions, the spirit of collaborative care, and what each provider is bringing to the table. 12:22 • Kate, tell us about why you come back to this conference every year. 17:32 • What challenges did you overcome to move the needle forward in diet and GI conditions? 19:14 • Chey, can you talk about the correlation between stress and diet when it comes to IBS? 24:21 • How are we dealing with the ramifications of GLP-1s? 29:33 • As providers, what is your first instinct when patients tell you they started GLP-1s? 32:28 • How is the community going to help listeners weed through Internet noise to find accurate information? 35:01 • Group discussion on the rise of severe constipation. 41:31 • Who decides to send patients for colectomy consultations? 43:33 • Is there anything else you want to share or highlight from the conference? 47:25 • Thank you all 48:58 • Thanks for listening 49:42 Erica Dermer is an IBS and Celiac Disease patient who hosts the blog and podcast series. Amanda Lynett MS, RDN, is a registered dietitian with her masters. Amanda is with the Division of Gastroenterology at Michigan Medical in Ann Arbor. Jeffrey Roberts, MSEd, BSc, is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS. Kate Scarlata, MPH, RDN, is a US-based dietitian with over 30 years of experience. Kate’s expertise is in gastrointestinal disorders and food intolerance. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more Tuesday Night IBS, be sure check out and to follow and subscribe to their podcast. Disclosures: Chey and Roberts report no relevant financial disclosures. Scarlata reports stock options with Epicured LLC and FODY Food Company, financial support from Dr. Schar, Mahana Therapeutics, Nestle Health Science, Olipop, Pendulum, QOL Medical. /episode/index/show/guttalk/id/37965405

Dedication, Innovation, Inspiration with Miguel Regueiro, MD 06/25/2025

Dedication, Innovation, Inspiration with Miguel Regueiro, MD In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. • Intro :58 • The interview/about Regueiro 1:03 • Tell us about your family and where you grew up. 1:24 • How did you get interested in medicine? 2:16 • Who were your early influences? 4:18 • What is the medical home? 5:57 • How did you develop the idea to apply the medical home model to IBD? 7:45 • Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 • Why hasn’t this model become standard of care for patients with complex IBD? 14:13 • What has worked, and what hasn’t worked when it comes to adopting an integrative care medical home model? 18:15 • Are there themes patients share as to why they wouldn’t want to be enrolled in a medical home? 21:28 • What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 • What have you learned in this position at Cleveland Clinic? 25:23 • Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 • How would you recommend that people prepare for having a position like this? 27:34 • Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 • With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 • What are the challenges that you still see in the ways we are using telehealth? 39:05 • What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 • Thank you, Miguel 42:55 • Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Regueiro, follow on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC. /episode/index/show/guttalk/id/37146795

Managing Uncertainty Around AI Technology with Ryan Stidham, MD 05/14/2025

Managing Uncertainty Around AI Technology with Ryan Stidham, MD In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. • Intro :24 • The interview/about Stidham :36 • Tell us about your family and where you grew up. 1:14 • How did you embrace changes in technology growing up? 3:07 • What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator? 6:05 • What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 • Can you give a quick overview of what these tools and technologies entail? 12:52 • What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 • Where did your interest in AI come about? 20:26 • You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 • How do we change the way we train GI doctors, and should we start making these changes today? 26:38 • With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 • What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 • What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 • Thank you, Ryan 44:04 • Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Stidham, follow on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc. /episode/index/show/guttalk/id/36563545

“The Fourth Shift”: Embracing the roles of social media and AI in health care with Austin Chiang, MD (Crossover with Physicianary) 03/26/2025

“The Fourth Shift”: Embracing the roles of social media and AI in health care with Austin Chiang, MD (Crossover with Physicianary) In this special crossover episode with Physicianary, previous Gut Talk guest, Austin Chiang, MD, and Physicianary host, Hansa Bhargava, MD, discuss the influence of social media in medicine and how AI continues to change the health care landscape. • Intro 0:30 • Austin Chiang, MD, MPH 0:36 • Tell us about your journey. 1:02 • How did you get involved with being a social media officer at your institution? 3:58 • Where do you think doctors should see themselves in the future of social media in medicine? 6:49 • What are the ways in which you see AI tech making a difference? 9:12 • Do you agree that it is helpful for doctors to be involved with product development and integration on an industry level? 12:14 • Can you give us some insight on the process of putting through new CPT codes as a company? 14:41 • Tell me more about your book, . What motivated you to write this book, and what do you think people will get out of it? 18:35 • If you were the “king of health care”, what would you work on first? What is the most important aspect of health car that you think needs fixing? 21:23 • What’s your favorite food? 25:24 • How to reach Chiang. 26:01 • Thanks 26:20 Austin Chiang, MD, MPH, is the first chief medical officer for the endoscopy business of the global leader in health technology. He is also currently an assistant professor of medicine at an academic teaching hospital in Philadelphia, PA, and serves as the director of the Endoscopic Weight Loss Program. Listen to Gut Talk’s very first episode with Dr. Chiang from 2019, . We’d love to hear from you! Send your comments/questions to . Follow us on X . Follow Dr. Bhargava on X and on Instagram . Follow Dr. Chiang everywhere on social media . Disclosures: Bhargava reports no relevant financial disclosures. Chiang reports he is the chief medical officer for Medtronic Endoscopy. /episode/index/show/guttalk/id/35867845

The Next Generation of GI with Prateek Sharma, MD 02/27/2025

The Next Generation of GI with Prateek Sharma, MD In this podcast episode, Prateek Sharma, MD, about how program directors can help shepherd GI fellows into clinical research spaces, providing quality exams for upper endoscopy and more. • Intro :24 • The interview/about Sharma :43 • Tell us about your family and where you grew up. 1:00 • Did you encourage your son to go into medicine? 2:17 • What kinds of doctors were your parents? 3:40 • Who were your big, early influences? 4:08 • If you didn’t always want to be a doctor, what convinced you to change your mind? 6:11 • When did you make the decision to go into academic medicine as a career? 7:16 • Are you seeing fewer and fewer fellows interested in pursuing a career in academic medicine? […] Are there ways to counsel fellows to be more interested in this type of work? 9:49 • How long have you been a program director, and are you still enjoying the work? 13:58 • How did you choose to into internal medicine and GI? 17:22 • As leaders of academic research centers, what have you done or plan to do in the face of potential cuts to the NIH overhead rates? 18:40 • How are we doing right now as a country and globally in terms of early detection of Barrett's neoplasia? 22:08 • Why has performing high-quality surveillance and screening of procedures like colonoscopy been so much more successful than performing high-quality exams for upper endoscopy? 25:33 • If the biggest hurdle to performing these exams is time, do you feel that more education around how to perform a high-quality exam will move the needle, or are other incentives needed? 28:32 • Do you think AI-based detection is overhyped or underhyped in GI? 30:33 • What are your thoughts on DNA-based testing for conditions like Barrett’s neoplasia, and how should they be incorporated into standard practice? 34:24 • What are your priorities as president of the this year? 38:42 • What do you see as the biggest threats or concerns to gastroenterologists? 42:25 • Final thoughts? 46:32 • Thank you, Prateek 47:13 • Thanks for listening 47:15 Prateek Sharma, MD, FASGE, FACP, FACG, is professor of medicine and director of the GI fellowship program at the University of Kansas School of Medicine. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Sharma, follow @KUcancercenter and @ASGEendoscopy on X and Instagram. Disclosures: Berry and Chey report no relevant financial disclosures. Sharma reports consulting for Boston Scientific Corporation, CDx Labs, Cipla, Exact Sciences, Medtronic, Olympus Corporation, Salix Pharmaceuticals, Samsung Bioepis and Takeda and provides grant/research support to ERBE USA Inc., Fujifilm Holdings America Corporation, Ironwood Pharmaceuticals Inc. and NEC. /episode/index/show/guttalk/id/35458040

Living the American Dream with Maria Abreu, MD 01/22/2025

Living the American Dream with Maria Abreu, MD In this podcast episode, Maria Abreu, MD, current president of the AGA, discusses the unique upbringing of health care professionals who are children of immigrants, formal versus on-the-job leadership training and more. • Intro :24 • The interview/about Abreu :31 • Can you tell us about where you grew up and the impact your family had on the work you’re doing now? :54 • Chey and Abreu on the in May 2024, which announced Abreu as the current AGA president and summarized her personal and professional life. 3:08 • Abreu on her father’s involvement with the Bay of Pigs invasion in Cuba. 7:00 • Chey and Abreu on the impact of an upbringing as children of immigrants. 12:02 • How did you get interested in GI, specifically in IBD? 13:00 • When did it become apparent to you that you were interested in more than traditional academia and clinical medicine, and wanted to inspire and have a broader impact? 17:37 • What would you say to a younger physician or someone earlier in their career about formal leadership training versus on-the-job training? […] Do you think this generation needs formal training in how to manage people as health care becomes more complex? 21:11 • Do you think that the future of academia and the phenotype of who is going to lead in academic divisions will change? 28:40 • What are your priorities during your presidential year at AGA? 34:24 • What have you learned so far as president of the AGA? Has anything struck you as surprising? 42:03 • Thank you, Maria 44:12 • Thanks for listening 44:45 Maria T. Abreu, MD, is the current president of the American Gastroenterological Association. She is the fifth woman to lead AGA as president and the association’s first Latino president. Dr. Abreu currently serves as the Martin Kalser Endowed Chair of Gastroenterology; professor of medicine, microbiology and immunology; and director of the Crohn’s and Colitis Center at the University of Miami. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Abreu, follow on X. Disclosures: Berry and Chey report no relevant financial disclosures. Abreu reports receiving consultant fees from serving on pharmaceutical advisory boards. /episode/index/show/guttalk/id/34955355

How GIs can recapture GI with Larry Kosinski, MD 12/18/2024

How GIs can recapture GI with Larry Kosinski, MD In this podcast episode, Larry Kosinski, MD, founder of SonarMD, discusses reclaiming GI services for patients and physicians, developing new tools for IBD patients and more. • Intro :24 • The interview/about Kosinski :29 • Can you tell us about your upbringing and the experiences that got you to where you are today? What got you interested in gastroenterology? :55 • Of the many “chapters” in your story, can you talk about your merger and acquisition experience in the medical field? How has the process of different GI groups coming together changed over time? 5:40 • Why did the investors of want to confine activities to just IBD and not scale it? 20:49 • Chey and Kosinski on the issues of moving away from patients being at the center of the decision-making and equal partnership in mergers and acquisitions. 22:03 • Chey and Kosinski on what drives physician burnout in gastroenterology. 25:06 • Do you feel that solutions focused on addressing cost in IBD is going to be as effective as solutions in addressing costs associated with functional diseases? 28:02 • What do you see next for SonarMD, and how has your own transition into your next “chapter” been? 32:24 • Berry, Chey and Kosinski on the development of tools to assist patients with IBD and diagnose GI conditions. 40:10 • What have you learned from the different projects you have worked on, and what advice would you give gastroenterologists interested in this type of innovation? 42:20 • Thank you, Larry 44:09 • Thanks for listening 44:33 Lawrence R. Kosinski, MD, MBA, AGAF, FACG, is a retired gastroenterologist who practiced for 35 years in suburban Chicago and is one of the founders of Illinois Gastroenterology Group, the largest independent GI practice in Illinois. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Kosinski, follow on X. Disclosures: Berry, Chey and Kosinski report no relevant financial disclosures. /episode/index/show/guttalk/id/34500795

Evolving the relationship between the AGA and Gastroenterology with Tom Serena 11/20/2024

Evolving the relationship between the AGA and Gastroenterology with Tom Serena In this podcast episode, Tom Serena, chief executive officer of the American Gastroenterological Association, discusses the role of private equity in specialty societies, the hunger to be involved in innovation and more. • Intro :24 • The interview/about Serena :29 • Can you tell us about your upbringing and how it helped you become who you are today? :50 • Were there certain early individuals or experiences that you think have been impactful or important to your career today? 1:43 • Have you always been a natural leader, or did you grow into it? 2:38 • What are some things you learned from your coach? 3:30 • Is there a pathway that you unintentionally took that led you to medical societies and medical society leadership? 5:09 • Over the thirty years you have been involved with the , when did you know that you were going to be a core part of the leadership team? 6:38 • How have you seen the GI field change over the last thirty years? 8:24 • Do you think there has been a shift in the culture of our specialty for major organizations like AGA to be more open to a wider range of physicians and stake holders? 11:00 • Where do you think we’re going over the next few years with private equity? 14:08 • Can you tell us more about the AGA’s ? What prompted the AGA to partner with venture capital and how has the experience been so far? 19:19 • Are there things that organization leaders are more likely to invest or not invest in? 21:47 • Berry, Chey and Serena on non-traditional ways physicians are looking to make use of their medical training. 23:24 • How have larger legacy societies like AGA and ACG view the emergence of more nuanced clinical societies, and how do they impact the way the AGA tries to execute its mission? 27:05 • Can you talk about ABIM’s impact on health care and the GI specialty? 30:01 • What are some of the biggest challenges facing AGA and GI as a field moving forward? 33:17 • Outside of the Opportunity Fund, what are other ways that the AGA is working to solve challenges around physician burnout, autonomy and reimbursement? 34:43 • Any life lessons you want to share with listeners? 36:22 • Thank you, Tom 37:39 • Thanks for listening 37:58 Tom Serena is chief executive officer of the American Gastroenterological Association. Tom joined AGA in 1994 and has served as the organization’s CEO since 2010. His previous role was VP of finance. He has been heavily focused on governance, helping the governing board to become the stewards of AGA’s future, with an emphasis on strengthening board - committee - staff relationships. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Serena, follow on X. For more from the AGA, visit and follow on X. Disclosures: Berry and Chey report no relevant financial disclosures. Serena reports he is an investor in the GI Opportunity Fund. /episode/index/show/guttalk/id/34033782

Predicting the future of GI with Brad Stillman 10/23/2024

Predicting the future of GI with Brad Stillman In this podcast episode, Brad Stillman, executive director at American College of Gastroenterology, discusses adapting with the GI landscape to prevent physician burnout, the role organizations play in ensuring physicians have the right tools to aid patients and more. • Intro :24 • The interview/about Stillman :35 • Can you tell us about your background? 1:17 • Who are your early influences? Who was foundational for the way you think and the person you are? 1:54 • Since your father was an artist, did you ever think about a career in art? 5:11 • How did you choose law as your vocation? 7:23 • From law, how did you get to the American College of Gastroenterology (ACG)? 8:47 • Over the twenty-three years that you have been involved with ACG, what has struck you about how gastroenterology has changed as a subspecialty and as a profession? 14:26 • Chey and Stillman on the structural challenges facing GI practices and screenings. 18:01 • What needs to happen to address the crisis of training additional gastroenterologists to meet rising demands? 23:39 • Chey, Berry and Stillman on creative solutions and being disruptive innovators in medical education reform. 29:09 • How has the ACG changed over the course of your tenure? What have the most profound changes been in this organization? 33:07 • Outside of education, how has it been managing the distinct components of the ACG, and what do you see in the future for the structure of the ACG? 37:57 • Do you have any “Stillman quotes” you’d like to share with us? 44:17 • Can you share anything about the upcoming strategic plan that is slated to be released at the ? 46:33 • Thank you, Brad 49:10 • Thanks for listening 49:29 Brad Stillman is the executive director at American College of Gastroenterology, the leading professional organization for GI clinicians with more than 20,000 members. He oversees all aspects of the College as well as the ACG Institute for Clinical Research and Education where he also serves on the board. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Stillman, follow on X. Disclosures: Berry, Chey and Stillman report no relevant financial disclosures. /episode/index/show/guttalk/id/33582062

“Food: The Main Course with Dr. William Chey & Amanda Lynett, MS, RDN” – Crossover with Tuesday Night IBS Podcast 09/10/2024

“Food: The Main Course with Dr. William Chey & Amanda Lynett, MS, RDN” – Crossover with Tuesday Night IBS Podcast In this special crossover podcast episode, Tuesday Night IBS host Jeffrey Roberts, MSEd, BSc, and Kate Scarlata, MPH, RDN, are joined live by William Chey, MD, and Amanda Lynett, MS, RDN, at FOOD the Main Course Conference in Ann Arbor, MI. · Intro :02 · The interview/about Scarlata :27 · About Chey 1:07 · About Lynett 1:53 · Chey, over the course of your career, what prompted this area of interest for you? 2:47 · When did you first hear about FODMAPs in relationship to IBS, and was there an “a-ha” moment that made you think that this would become something major in the future? 5:38 · What was your goal with this conference, FOOD the Main Course? 10:28 · Amanda, how do you go about putting a conference like this together? 14:09 · Where do you see GI nutrition going? What are some new updates in this area for dieticians? 18:45 · Amanda, what personally prompted you to go into GI nutrition? 22:03 · Chey, where do you think IBS care is going, and are we succeeding in helping patients? 24:37 · Do you feel that there is a role for supplements, prebiotics and probiotics in managing IBS? 28:26 · What about mast cell stabilizers? 30:49 · Do you have any recommendations right now for health care providers caring for patients with IBS? 33:56 · Do you think there is an opportunity to educate providers about pelvic floor physical therapy from a diet and awareness perspective? 39:21 · Amanda, as an expert GI RD, where do you see IBS care going, and what hopeful messages can you provide to people living with this condition? 42:41 · If you could speak to other health care professionals that work in GI, what is an important component that should be considered when offering nutrition care for patients living with a GI disorder? 44:17 · Thank you, Dr. Chey and Amanda 49:26 · Thanks for listening 49:42 Amanda Lynett MS, RDN, is a registered dietitian with her masters. Amanda is with the Division of Gastroenterology at Michigan Medical in Ann Arbor. Jeffrey Roberts, MSEd, BSc, is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS. Kate Scarlata, MPH, RDN, is a US-based dietitian with over 30 years of experience. Kate’s expertise is in gastrointestinal disorders and food intolerance. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more Tuesday Night IBS, be sure check out and to follow and subscribe to their podcast. Disclosures: Chey and Roberts report no relevant financial disclosures. Scarlata reports stock options with Epicured LLC and FODY Food Company, financial support from Dr. Schar, Mahana Therapeutics, Nestle Health Science, Olipop, Pendulum, QOL Medical. /episode/index/show/guttalk/id/32995712

Tom McCourt on discovery, trust, friendship and courage 08/21/2024

Tom McCourt on discovery, trust, friendship and courage In this podcast episode, Tom McCourt, chief executive officer of Ironwood Pharmaceuticals, discusses the evolving relationship between physicians and pharma, breakthroughs in GI drugs and more. • Intro :59 • Welcome to this episode of Gut Talk 1:23 • The interview/about McCourt 1:32 • Tell us about your family and where you grew up. 2:15 • What did you take away from your football career at University of Wisconsin? 4:19 • How long were you a clinical pharmacist? 7:57 • McCourt on his experience as a health science associate. 8:55 • Where is the line between academics and the pharma industry? 10:49 • When you launched drugs like omeprazole and esomeprazole, did you have any idea what impact they would have? 13:00 • What changed to make the pharma industry go from respected to villainized? 16:39 • What’s your perspective on innovation and billing architecture for pharmaceuticals? […] Where do you think we’re going to see the most exciting changes in the near-term? 19:33 • Chey and McCourt on challenges the US health care system faces in comparison to other countries. 24:47 • How can we make breakthrough drugs and technology available to everyone without stifling innovation? 27:05 • Did patients valuing their quality-of-life factor into your decision to switch from AmGen to Ironwood Pharmaceuticals? 29:12 • From a pharmaceutical perspective, do you think there are examples of successful health policy? 36:30 • Thank you, Tom 42:13 • Thanks for listening 43:20 Tom McCourt is the chief executive officer of Ironwood Pharmaceuticals, a commercial biotechnology company working to revolutionize the treatment of gastrointestinal (GI) diseases and redefine the standard of care for millions of patients. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from McCourt, follow on X. Disclosures: Berry and Chey report no relevant financial disclosures. McCourt is chief executive officer and a member of the board of directors of Ironwood Pharmaceuticals; serves on the board of directors and member of the compensation committee of Pliant Therapeutics, Inc., a public company, and on the board of trustees for the American Society of Gastrointestinal Endoscopy (ASGE). /episode/index/show/guttalk/id/32669927

Embracing change to grow as a person and a leader with John Inadomi, MD 06/26/2024

Embracing change to grow as a person and a leader with John Inadomi, MD In this podcast episode, John Inadomi, MD, chair of the department of internal medicine at University of Utah Health, discusses the value of mentorship, qualities a leader should possess and more. • Intro :59 • Welcome to this episode of Gut Talk 1:23 • The interview/about Inadomi 1:30 • Tell us about your family and where you grew up. 2:59 • Inadomi on the impact World War II had on his family. 3:47 • Chey and Inadomi on the ways immigrants approached being American post-World War II. 4:33 • How did you end up in medicine after receiving a mechanical engineering degree from MIT? 6:32 • How did you go from bionics to polyps/GI? 8:00 • What did you learn from your experiences playing water polo in college? 10:31 • How did you end up at the University of New Mexico? 13:00 • What did Amnon Sonnenberg, MD, MSc, teach you? 16:04 • How do you view and embrace change? 18:27 • When did you catch the bug of wanting to lead faculty? […] Did you have mentorship specifically on health system leadership? 24:30 • How have you learned these leadership characteristics and skills that are not an inherent part of physician training? Do you think there is going to be a change in leadership development moving forward? 29:59 • For people thinking about advancement opportunities in leadership, what is the mindset you have to develop as a successful division chief or a successful department chair? 33:55 • What do you think are the biggest challenges facing academic gastroenterology or academic internal medicine? […] How can we physicians be aware of and mitigate these challenges? 38:36 • How are academic medical centers going to survive? 41:39 • Do you see the loss of physician autonomy and burnout getting better? 43:29 • What has been your favorite golf course that you have played on? 46:36 • Thank you, John 47:48 • Thanks for listening 48:14 John M. Inadomi, MD, is the Jon M. Huntsman presidential endowed chair, and the chair of the department of internal medicine at University of Utah Health. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Inadomi, follow him on X . Disclosures: Berry and Chey report no relevant financial disclosures. Inadomi reports grant support from Exact Sciences. /episode/index/show/guttalk/id/31896367

A Gastroenterologist’s Journey to Innovation and Entrepreneurship with Tom Shehab, MD 04/24/2024

A Gastroenterologist’s Journey to Innovation and Entrepreneurship with Tom Shehab, MD In this podcast episode, Tom Shehab, MD, managing partner at Arboretum Ventures, discusses supporting “doctorpreneurs”, alternative career paths for physicians and more. • Intro :59 • Welcome to this episode of Gut Talk 1:23 • The interview/about Shehab 1:30 • Where did you grow up and who were your early influences? 2:02 • Can you give us some examples of your parents’ sacrifices that made your career possible? 3:19 • What did you learn from being an athlete and your time playing football at Bowling Green State University? 4:38 • Tell us about your education. 6:21 • How did you make the move from an academic career to venture capitalist? 7:03 • What can you teach our audience about paving this path? 10:55 • Is it better to thoughtfully consider major career decisions and changes, or just leap before you look? 12:45 • What other advice would you give budding “doctorpreneurs”? 14:35 • How are GI and liver a space for venture investment? 18:01 • Outside of endoscopy, why is there a dearth of information in the GI specialty from a venture perspective? 21:36 • Do you see this changing in the right direction toward GI specialists paying more attention on what needs attention and expertise, or are macroeconomic incentives preventing us from taking that perspective? 24:37 • What advice do you have for someone who is thinking about an alternative career pathway? 33:08 • What is the next step or time commitment for aspiring “doctorpreneurs” with ideas? 37:26 • What about the venture world? How should physicians go about funding and investing in their ideas? 41:33 • What are some of the upcoming macroeconomic trends that will impact GI in the short- and long-term? 46:47 • Thank you, Tom 52:02 • Thanks for listening 52:55 Tom Shehab, MD, practiced medicine for 15 years as a gastroenterologist serving as chair of medicine at Integrated Health Associates (IHA), and as chief of staff at St. Joseph Mercy Hospital for more than 1,000 physicians. Shehab currently serves as a board director for Avation Medical, Boomerang Medical, Fifth Eye, Motif Neurotech, SonarMD and Virtual Incision and led Arboretum’s investment in nVision Medical, which was acquired by Boston Scientific in 2018. Shehab also serves as a board member for several health care innovation initiatives, including the Cleveland Clinic Medical Device Advisory. He is also on the board of trustees for Bowling Green State University. We’d love to hear from you! Send your comments/questions to . Follow us on X . For more from Shehab, follow him on X . Disclosures: Berry, Chey and Shehab report no relevant financial disclosures. /episode/index/show/guttalk/id/30965938

The Development of GI Psychology with Megan Riehl, PsyD 12/06/2023

The Development of GI Psychology with Megan Riehl, PsyD In this podcast episode, Megan Riehl, PsyD, discusses symptoms and solutions in GI psychology, building educational tools for patients and physicians on GI psychology and more. • Intro :02 • Welcome to this episode of Gut Talk :23 • The interview/about Riehl :33 • Riehl on early influences on her career. :48 • Growing up, how did your family system influence you? 2:12 • How did you get into psychology, and who were the people that influenced you to go into this field? 3:45 • How did you become interested in GI psychology? 5:27 • Chey and Riehl on risk-taking behavior and building the GI psychology program at Michigan. 7:29 • Were there other fields you were considering as a subspecialty in psychology? 10:23 • Is there something physiologic about gastroenterology that makes the path to psychology more appropriate than other specialties in the health care system? 13:33 • Can you explain the difference between a GI psychologist and a general psychologist, and what types of patients will benefit most from GI psychology? 16:12 • Do you get inappropriate referrals from clinicians, such as patients with compliance and adherence issues or lack of belief in the validity of their diagnosis? 19:33 • Do you think the term ‘GI psychologist’ is limiting, and have you thought of different words or terminology we can use to refer to this type of work? 22:20 • Berry, Chey and Riehl on potential benefits, risks and . 24:37 • Berry and Riehl on the issues facing patients’ ability to access GI psychology, and how digital therapeutics can potentially address these issues. 28:04 • What are the main types of interventions in GI psychology, and what do they do? 31:48 • Riehl on her upcoming book, , co-written with Kate Scarlata, RDN. 36:09 • Thank you, Megan 38:40 • Thanks for listening 38:55 Megan Riehl, PsyD, is a GI psychologist with expertise in psycho-gastroenterology and the management of GI conditions. She is the clinical director of the GI behavioral health program at the University of Michigan, where she has a full-time clinical practice, leads GI behavioral health trainings and provides peer consultation. We’d love to hear from you! Send your comments/questions to . Follow us on X, formerly known as Twitter, . For more from Megan, follow on X, formerly known as Twitter. Disclosures: Berry and Chey report no relevant financial disclosures. Riehl reports she is a co-parent owner of GI OnDemand with Gastro Girl, Inc. /episode/index/show/guttalk/id/28955733

Creating the Field of GI Nutrition with Kate Scarlata, RDN 09/20/2023

Creating the Field of GI Nutrition with Kate Scarlata, RDN In this podcast episode, Kate Scarlata, MPH, RDN, discusses how to help patients avoid over restricting their diets, the use of digital therapeutic tools in dietetics and more. • Intro :02 • Welcome to this episode of Gut Talk :23 • The interview/about Scarlata :31 • Scarlata on her family and growing up in a family of nine children. 1:02 • Who was more influential in shaping you? Was it your family, or people outside the family unit? 3:40 • What got you interested in diet and nutrition? 6:27 • Are there any defining moments personally or professionally that affected the direction of your career? 8:02 • Can you tell us about your first job as a GI dietician and how it led to your role in the field today? 12:17 • Berry and Scarlata on GI patient motivations and how they differ from the average patient. 16:51 • Are there things that you think are unique from a dietetics perspective to build that rapport with the patient and walk them back from deeply rooted thoughts they may have about their diet? 17:49 • Have you encountered situations with patients where you felt like you could not move forward without the assistance of other specialists such as a trained GI psychologist? 19:47 • Chey and Scarlata on disordered eating and eating disorders and red flags to help identify and assist these patients. 22:25 • Are you utilizing the FODMAP Gentle or bottom-up approach? 27:27 • Berry, Chey and Scarlata on the emergence of digital automated tools developed to help patients get access to therapies without the use of a trained clinician. 29:11 • Can you talk about the patient advocacy efforts you have been involved with, including the IBelieveinyourStory campaign and the EndHungerPain initiative? 34:43 • Chey, Berry and Scarlata on the economic challenges facing multidisciplinary GI care and getting patients access to dietary needs including resources like . 41:29 • Scarlata on her upcoming book, , co-written with Megan Reihl, PsyD. 43:52 • Thank you, Kate 45:06 • Thanks for listening 45:17 Kate Scarlata, MPH, RDN is a US-based dietitian with over 30 years of experience. Kate’s expertise is in gastrointestinal disorders and food intolerance. Kate is the author of numerous books and articles on digestive health topics including the New York Times Best Seller, The 21 Day Tummy Diet. We’d love to hear from you! Send your comments/questions to . Follow us on X, formerly known as Twitter, . For more from Kate Scarlata, follow on X, formerly known as Twitter. Disclosures: Berry and Chey report no relevant financial disclosures. Scarlata reports stock options with Epicured LLC and FODY Food Company, financial support from Dr. Schar, Mahana Therapeutics, Nestle Health Science, Olipop, Pendulum, QOL Medical. /episode/index/show/guttalk/id/28092080

Private Practice Dietetics in GI with Tamara Duker Freuman, MS, RD 07/19/2023

Private Practice Dietetics in GI with Tamara Duker Freuman, MS, RD In this podcast episode, Tamara Duker Freuman, MS, RD, CDN, discusses how the work of gastroenterologists and dieticians can inform each other, approaching GI conditions as new science emerges and more. • Intro :02 • Welcome to this episode of Gut Talk :23 • The interview/about Duker Freuman :30 • How did your childhood environment and early education lead you to become a dietician? :41 • Can you tell us about how your experiences have had an impact on the way you treat your patients as a dietician? 1:47 • How Duker Freuman’s books, and , provide information about clues that can help providers better understand the causes of patients’ symptoms. 3:22 • Are dieticians trained differently than doctors when it comes to motivational interviewing versus fact-seeking to learn about patient history? 4:30 • About the JAMA Network studies on and 7:12 • What eventually drew you to dietetics, and then GI dietetics? 7:43 • When you went into GI nutrition, was it already a recognized specialty? 10:52 • Were you an early adopter of the low-FODMAP diet? 13:27 • How did the GI community react to the news of low-FODMAP at the time? Was this science well-embraced by physicians when it came out? 14:50 • With low-FODMAP, are you a top down or a bottom up person? Do you have a preference? 19:03 • In your book you discuss the ten main causes for bloating. What are the main causes we should be thinking about, and which are the most common in your experience? 20:22 • You talk about the “food baby twins”, gastroparesis and abdomino-phrenic dyssynergia, in your book. Can you tell us about that? 22:51 • Do you have any recommendations for abdomino-phrenic dyssynergia, like diaphragmatic breathing, and what has worked that you have recommended to patients? 24:02 • With the challenges of insurance reimbursement for dietetics and getting patients access to this type of information, can you provide enough value with one visit with a patient, or is multiple visits with a dietician required in order to move the needle? 25:19 • What do you think about histamine intolerance? How do you identify it and is there a low-histamine diet that people can use now? … What about Mediterranean? 28:27 • How have you trained yourself and the dieticians that you work with to think about and incorporate cultural and lifestyle sensitivity into dietary recommendations? Are there best practices to embrace that, or is this a challenge of dietetics? 36:01 • What was it like joining New York Gastroenterology Associates (NYGA) when they became a large group practice? … What was it like bringing on additional dieticians and continuing to grow that part of NYGA’s care delivery? 39:40 • Thank you, Tamara 43:41 • Thanks for listening 43:59 Tamara Duker Freuman, MS, RD, CDN, is a New York-based registered dietitian, author and nationally-known expert on medical nutrition therapy for gastrointestinal diseases. We’d love to hear from you! Send your comments/questions to . Follow us on Twitter . For more from Tamara Duker Freuman, follow on Twitter and on Instagram. Disclosures: Berry, Chey, and Duker Freuman report no relevant financial disclosures. /episode/index/show/guttalk/id/27507942

The Future of Endoscopy with Doug Rex, MD 05/24/2023

The Future of Endoscopy with Doug Rex, MD In this podcast episode, Douglas Rex, MD, discusses the importance of intent-to-treat for colorectal screenings, how screening technology has transformed gastroenterology practice and more. • Intro :02 • Welcome to this episode of Gut Talk :23 • The interview/about Rex :32 • Where did you grow up, and what was your childhood like? :52 • What got you interested in medicine? 2:50 • How did your journey with GI start? 4:33 • How have those early days and formidable experiences of being in the lab impacted your career today and what you are more well-known for? 8:19 • Discussion on the and the 11:55 • Rex, Chey and Berry on the importance on the issue surrounding intent-to-treat in the setting of colorectal cancer screening 14:57 • Rex on the Multi-Society Task Force of Colorectal Cancer (MSTF) committee and how they come to decisions that influence how gastroenterologists practice daily 16:55 • Was it a difficult decision to move the threshold for colorectal cancer screening from 50 to 45? 20:41 • In an environment where there is a limited resource such as colonoscopy, are you struggling with volume at your institution? … What are some strategies that listeners can utilize to prioritize patients, seek other possibilities and manage volume? 22:28 • What’s the right way to approach the screening problem? … Where will this lead us ten years from now if all of us are spending our time in the endoscopy suite because of continued reduction in the age of screening while the prevalence of functional conditions and chronic diseases is also rising? 25:51 • How long do you think we’ll continue to rely upon screening colonoscopy as one of our primary means by which to screen for colon cancer? Are there any technologies on the horizon that will eat into the share of screening colonoscopy? 28:55 • What is your perspective on AI and how it can impact not only adenoma detection rate and polyp detection, but also clinical workflows such as documentation time? … Are you concerned about the new generation of clinicians being trained on and relying on these tools? 34:07 • What have you learned in terms of best practices for the right and wrong ways to work with industry? 38:07 • Thank you, Dr. Rex 40:25 • Thanks for listening 40:43Douglas K. Rex, MD, is a distinguished professor emeritus at Indiana University School of Medicine and a full-time clinical gastroenterologist at Indiana University Hospitals. We’d love to hear from you! Send your comments/questions to . Follow us on Twitter . For more from Dr. Rex, follow on Twitter. Disclosures: Chey and Berry report no relevant financial disclosures. Rex is a consultant for Boston Scientific, Braintree Laboratories, Medtronic, Norgine, and Olympus Corporation. He provides research support at Braintree Laboratories, Erbe USA Inc, Medivators, and Olympus Corporation and is a shareholder of Satisfai Health. /episode/index/show/guttalk/id/26936388

The Future of Care for Disorders of Gut-Brain Interaction with the ROME Foundation 04/03/2023

The Future of Care for Disorders of Gut-Brain Interaction with the ROME Foundation In this podcast episode, Douglas Drossman, MD, and Johannah Ruddy MEd, discuss methods of destigmatizing chronic illness for patients and physicians, technology’s effect on the doctor-patient relationship and more. • Intro :02 • Welcome to this episode of Gut Talk :23 • The interview/about Drossman and Ruddy :30 • About Ruddy’s professional and personal background regarding DGBI patients 1:40 • For Ruddy: What was the transformative moment that made you want to get so involved in patient advocacy? 3:39 • For Drossman: How do doctors talk more effectively to patients? 5:49 • Chey and Drossman on the objectification of patients and physicians 9:00 • Are there ways to teach people to re-inject the joy of the patient-physician interaction? … How do physicians re-frame the way that they think about interacting with patients? 10:00 • Ruddy, Chey and Drossman on the value of narrative history taking 13:35 • Drossman on the connection between psychosocial information and the onset and perpetuation of patient symptoms 15:29 • Why are there such big gaps in care for patients with disorders of gut-brain interaction and visceral hypersensitivity? 16:00 • About the Linedale study on clear language versus qualified language for IBS diagnoses 18:55 • Chey on the flipsides of confident diagnoses 22:22 • Do gastroenterologists and primary care doctors have the tools available to treat these conditions? 24:15 • Thoughts on how technology has affected the physician-patient relationship 27:38 • How do you deal with the systematic pressures that exist on most brick-and-mortar gastroenterologists today? 31:21 • Tell us about the main goals and contents of your book, 32:38 • What are the common threads that emerged from your studies in the book for doctors to think about? 34:03 • Ruddy’s patient insights on where physicians can think about prioritizing in their care 36:47 • Thank you, Dr. Drossman and Ms. Ruddy 38:33 • Thanks for listening 39:14 Douglas Drossman, MD, is a professor emeritus of medicine and psychiatry in gastroenterology at UNC. He is a fellow of the American College of Physicians, a master of the American College of Gastroenterology, past-president of the American Psychosomatic Society. Johannah Ruddy, MEd, is an educator, researcher and writer and currently serves as the chief operating officer and executive director of the Rome Foundation. Ruddy co-founded and is the director of Tuesday Night IBS community on Twitter. Check out: Gut Feelings: Disorders of Gut-Brain Interaction and The Patient-Doctor Relationship and Gut Feelings: The Patient’s Story We’d love to hear from you! Send your comments/questions to . Follow us on Twitter . For more from Dr. Drossman, follow him on Twitter . For more from Ms. Ruddy, follow her on Twitter . Disclosures: Chey and Berry report no relevant financial disclosures. Drossman reports affiliation with Ardelyx, Rome Foundation. Ruddy reports affiliation with Biomerica, Mahana Therapeutics, Rome Foundation and Tuesday Night IBS. /episode/index/show/guttalk/id/26426982

Health Care Innovation & Non-Traditional Care with Shivan Mehta, MD 01/25/2023

Health Care Innovation & Non-Traditional Care with Shivan Mehta, MD In this podcast episode, Shivan Mehta, MD, MBA, MSHP, discusses behavioral economics in patients and clinicians, the entrance of non-traditional entities in the health care space and more. Intro :02 Welcome to this episode of Gut Talk :23 The interview/about Mehta :30 How did you get to where you are now? What got you interested in medicine, and how did you end up with the role that you have today? :58 Can you elaborate more on the people who had an influence on you? 3:10 About behavioral economics 5:39 Are there tried and true theories in behavioral economics around what works to change patient behavior? 9:25 What about insurance companies with steerage? … Are there studies that show that those are different types of financial incentives, as opposed to paying someone? 15:45 Have we seen, or is there research on the effect of, pricing something lower in patients’ decision making in health care? 19:25 As an academic researcher and administrator, what do you think about the entrance of non-traditional entities in health care compared to the work that is being done by clinicians and at academic centers? 22:03 Do you see the move from fee-for-service to quality care happening? 26:41 Thoughts on the future of funding in health care 28:38 What do you think about the physician’s role in current and future innovation? 31:32 How do we create a generation of physicians who are thinking more innovatively and entrepreneurially? 34:51 Thank you, Dr. Mehta 41:43 Thanks for listening 41:50 Shivan Mehta, MD, MBA, MSHP, is associate chief innovation officer at Penn Medicine and associate professor of Medicine and Health Policy at the Perelman School of Medicine. We’d love to hear from you! Send your comments/questions to . Follow us on Twitter . For more from Dr. Mehta, follow on Twitter. Disclosures: Chey and Berry report no relevant financial disclosures. Mehta serves on a clinical advisory board for Guardant Health and receives grant funding from the National Institutes of Health. /episode/index/show/guttalk/id/25725114

The Different Facets of GI Leadership with Amy Oxentenko, MD 11/01/2022

The Different Facets of GI Leadership with Amy Oxentenko, MD In this podcast episode, Amy Oxentenko, MD, discusses the importance of adapting in her leadership roles and shares her thoughts on creating transparent, inclusive spaces in practice, and more. Intro :02 Welcome to this episode of Gut Talk :23 The interview & about Oxentenko :38 Were there people that influenced your decision to transition from advanced math to medicine? 1:59 How did you end up migrating towards a field like GI? 3:10 How did the smaller percentages of women in the field when you started make you feel and influence you as a gastroenterologist and leader? 5:36 About concerns on the sides of employers and prospective female employees regarding discussion of starting a family, parental leave in an interview 7:53 Can you tell us about the study you recently published on the biases towards female house officers? 11:55 Do you have advice for young women on how to approach that discussion with potential employers, and how we can handle this type of discussion? 13:54 Are there any life lessons you want to talk about in regard to the different roles you have had over the years? 15:54 What are your perspectives on what you learned from your experiences being a chair of medicine during the pandemic? 19:06 How did you adapt to a set of circumstances that are really different than your usual style of leadership? 22:15 Can you tell us about some of the tactical things you’re doing now to adapt to how patients have become accustomed to telehealth? 24:13 Are there any initiatives underway that may help the rest of us think about how to navigate this time as we all try to get back to normal and restore a sense of community? 27:21 About Maintenance of Certification (MOC) and Dr. Oxentenko’s efforts to create alternative pathways to the 10-year exam 29:31 As part of the executive chain and future president for the American College of Gastroenterology, where do you think the college should focus their attention in these next couple of years? 34:05 What are some of the tactical things that institutions can do to promote inclusivity that might not be as obvious? … What have you seen that actually moves the needle forward? 37:52 Thank you, Dr. Oxentenko 40:52 Thanks for listening 41:09 Amy Oxentenko, MD, is chair of the department of Medicine at the Mayo Clinic in Arizona. We’d love to hear from you! Send your comments/questions to . Follow us on Twitter . For more from Dr. Oxentenko, follow on Twitter. /episode/index/show/guttalk/id/24868458

Humanity in Medicine with Mitch Albom 08/30/2022

Discovering ERCP with Peter B. Cotton, MD 08/08/2022

Discovering ERCP with Peter B. Cotton, MD In this podcast episode, Peter B. Cotton, MD, FRCP, FRCS, professor of medicine at the Medical University of South Carolina, discusses the development and invention of the ERCP procedure, the innovation of digestive disease centers and more. Intro :02 Welcome to this episode of Gut Talk :23 About Cotton :23 The interview :37 Where did you grow up? :37 How did you get interested in gastroenterology? 1:38 That [trainees wanting to come to the endoscopy lab and not go to the basic science lab] must have put you in a difficult situation at times. How did you navigate that? 6:12 Could you tell us a little more about what that was like, from an operational perspective, of overseeing the endoscopy center, and perhaps how that role of operating in an endoscopy center as a trainee impacted you innovation in ER cepheid advanced endoscopy? 7:03 How flexible is the shaft of those initial endoscopes, and did you use sedation? 8:49 Is it a correct characterization that the building and innovation and inventions at this early stage in your career was really just to get the job done as opposed to you seeking out a role that was focused on inventing? 9:56 You were the only gastroenterologist at Middlesex for many years, correct? 10:52 How did that transition to Duke occur? … Did that [clinical load] drive a lot of your decision-making or was it more than that? 11:50 Where did the ERCP start? 15:11 How were you able to collaborate with other gastroenterologists and radiologists and surgeons? …What was that collaboration between these investigators that were really trying to drive this procedure forward like back in the Sixties and Seventies? 20:23 Were you able to pass endoscopic videos back and forth, or was that not really the way cases were shared? 21:36 About the Digestive Disorder Center at NUSC and Digestive Diseases Centers 24:43 Has it worked out the way you had envisioned? … What are the potential downfalls as people think about that type of Digestive Health Center model? 27:43 Summary of Cotton’s memoir, The Tunnel at the End of the Light: My Endoscopic Journey in Six Decades 31:34 You also have written books for young children as well. What prompted you to writing and teaching one of the most complicated procedures to your book about “Fred the Snake”? 32:10 What are you most excited about with regards to opportunities facing younger gastroenterologists moving forward, and what advice would you give them to seize those opportunities? 34:54 Thank you Peter 36:42 Thanks for listening 36:58 Peter B. Cotton, MD, FRCP, FRCS, is professor of medicine at the Medical University of South Carolina. We’d love to hear from you! Send your comments/questions to . Follow us on Twitter Disclosures: Berry and Chey report no relevant financial disclosures. Cotton reports no relevant financial disclosures. /episode/index/show/guttalk/id/23994744

Perspectives on Leadership, Education and the Future of Clinical Care in IBS with Lin Chang, MD 05/03/2022

Perspectives on Leadership, Education and the Future of Clinical Care in IBS with Lin Chang, MD In this podcast episode, Lin Chang, MD, vice-chief of Vatche and Tamar Manoukian Division of Digestive Diseases, discusses her path to GI, her interest in IBS and some of the newest therapies coming down the pipe and more. Intro :02 Welcome to this episode of Gut Talk :22 About Chang :28 The interview :46 Where did you grow up? :49 Who are your early role models? 3:50 How far along in college were you before you decided to apply for medical school? 4:58 How did you get interested in GI? 5:32 What advice would you give to the residents and fellows that you interact with in that regard? 8:42 As you started your career you weren’t necessarily thinking that you were going to be a clinical/academic icon … didn’t you start mostly as a clinician? 11:56 Early on when we started working together … you were the only woman in the room. How were you able to break through that glass ceiling and get into the room? 17:38 What advice do you give your fellows who want to get more involved? 22:12 How did you get interested in a condition like IBS? 24:02 Could you explain to our listeners what it means by the biopsychosocial model when referring to IBS? 26:21 Do you think that, in actuality, these could be completely separate diseases? 29:03 Discussion on the layers of IBS 32:26 Do you mind summarizing your key takeaways from an American Gastrological Association clinical practice update on the role of diet in patients with IBS? 38:03 Another document we’re working on right now is the first joint society (AGA, ACG) clinical practice guideline on treatment of chronic constipation … would you like to say a couple words about that one? 42:04 What does your future look like? What are you thinking is next for Lin Chang? 44:39 In your role as program director, what are the trends that you’ve noticed amongst trainees? 46:46 What are you most excited about with regards to the newer therapies and treatment paradigms, the new care delivery models that are on the horizon to help patients with IBS? 49:13 Lin, this has been a great discussion 51:00 Thanks for listening 51:37 Lin Chang, MD, is the vice-chief of Vatche and Tamar Manoukian Division of Digestive Diseases, program director of the UCLA GI Fellowship Program and the co-director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience. We’d love to hear from you! Send your comments/questions to . Follow us on Twitter Disclosures: Berry and Chey report no relevant financial disclosures. Chang reports no relevant financial disclosures. /episode/index/show/guttalk/id/22994165

Physician Entrepreneurship in GI with Joe Rubinsztain, MD 11/17/2021

Diversity, Equity and Inclusion in GI with Sophie M. Balzora, MD 08/03/2021

Virtual Reality in GI with Brennan Spiegel, MD 06/28/2021

Gut Talk

TOPICS